Clemens Mark W, Horwitz Steven M
Associate Professor, Department of Plastic Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Attending Medical Oncologist of Lymphoma, Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aesthet Surg J. 2017 Mar 1;37(3):285-289. doi: 10.1093/asj/sjw259.
Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Comprehensive Cancer Network (NCCN) annually publishes Clinical Practice Guidelines for Non-Hodgkin Lymphomas. For the first time, BIA-ALCL management will be included which signifies an important and needed guideline addition. The new BIA-ALCL guideline was achieved by a consensus of lymphoma oncologists, plastic surgeons, radiation oncologists, and surgical oncologists. NCCN guidelines focus on the diagnosis and management throughout the stages of many lymphoma subtypes based upon the most current data available. This article summarizes the essential recommendations and optimal therapeutic strategies of the NCCN guidelines critical to the plastic surgery community. We encourage international adoption of these BIA-ALCL treatment standards by our specialty societies across the oncology and surgery disciplines.
已发表的病例系列表明，对于乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）缺乏治疗标准化，在疾病的各个阶段都采用了各种各样的治疗策略。美国国立综合癌症网络（NCCN）每年都会发布非霍奇金淋巴瘤临床实践指南。首次将BIA-ALCL的管理纳入其中，这标志着一项重要且必要的指南补充。新的BIA-ALCL指南是由淋巴瘤肿瘤学家、整形外科医生、放射肿瘤学家和外科肿瘤学家共同达成的共识。NCCN指南基于现有最新数据，专注于多种淋巴瘤亚型各阶段的诊断和管理。本文总结了对整形外科界至关重要的NCCN指南的基本建议和最佳治疗策略。我们鼓励肿瘤学和外科学领域的专业协会在国际上采用这些BIA-ALCL治疗标准。
